Castro Valley, CA, United States of America

Thomas Zarembinski

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biotime, Inc.. Active years: 2018.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Zarembinski: Innovator in Hyaluronan-Based Hydrogels

Introduction

Thomas Zarembinski is a notable inventor based in Castro Valley, California. He has made significant contributions to the field of biomedical materials, particularly through his innovative work with hyaluronan-based hydrogels. His research focuses on enhancing the properties of these materials for various applications.

Latest Patents

Zarembinski holds a patent for "Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione." This invention provides methods, compositions, and kits relating to hyaluronan-based matrices that utilize oxidized glutathione as a crosslinking agent. His work in this area has the potential to advance the development of new therapeutic materials.

Career Highlights

Currently, Thomas Zarembinski is associated with BioTime, Inc., where he continues to explore innovative solutions in the biomedical field. His expertise in hydrogels and biocompatible materials has positioned him as a valuable asset in his organization.

Collaborations

Throughout his career, Zarembinski has collaborated with talented individuals such as Isaac Erickson and Nathaniel Doty. These partnerships have fostered a creative environment that encourages the development of groundbreaking technologies.

Conclusion

In summary, Thomas Zarembinski is a dedicated inventor whose work with hyaluronan-based hydrogels is paving the way for advancements in biomedical applications. His contributions to the field are noteworthy and continue to inspire innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…